Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stuart J Pocock

Showing results (101-110 of 349) with videos related to

Pageof 35
Sort By:
International Journal of Cardiology|August 21, 2007
Costs of an early intervention versus a conservative strategy in acute coronary syndromeDavid M Epstein, Mark J Sculpher, Tim C Clayton, et al.
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
European Heart Journal|December 10, 2024
Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialJoão Pedro Ferreira, Faiez Zannad, Francisco Vasques-Nóvoa, et al.
European Journal of Heart Failure|November 30, 2020
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failureMilton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure|August 30, 2021
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trialMilton Packer, Faiez Zannad, Javed Butler, et al.
Contemporary Clinical Trials|November 22, 2007
Quality management of a large randomized double-blind multi-centre trial: the ACTION experienceBridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, et al.
The New England Journal of Medicine|November 16, 2010
Eplerenone in patients with systolic heart failure and mild symptomsFaiez Zannad, John J V McMurray, Henry Krum, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 23, 2020
Prioritised endpoints for device-based hypertension trials: the win ratio methodologyDavid E Kandzari, Graeme L Hickey, Stuart J Pocock, et al.
European Journal of Heart Failure|December 27, 2021
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-ReducedJoão Pedro Ferreira, Stefan D Anker, Javed Butler, et al.
European Heart Journal|December 8, 2021
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fractionJaved Butler, Milton Packer, Gerasimos Filippatos, et al.
Pageof 35

Showing results (101-110 of 349) with videos related to

Sort By:
Pageof 35
International Journal of Cardiology|August 21, 2007
Costs of an early intervention versus a conservative strategy in acute coronary syndromeDavid M Epstein, Mark J Sculpher, Tim C Clayton, et al.
Circulation. Heart Failure|March 23, 2012
When to stop a clinical trial early for benefit: lessons learned and future approachesFaiez Zannad, Wendy Gattis Stough, John J V McMurray, et al.
European Heart Journal|December 10, 2024
Anaemia, erythrocytosis, and empagliflozin in heart failure with preserved ejection fraction: the EMPEROR-Preserved trialJoão Pedro Ferreira, Faiez Zannad, Francisco Vasques-Nóvoa, et al.
European Journal of Heart Failure|November 30, 2020
Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failureMilton Packer, Javed Butler, Gerasimos Filippatos, et al.
European Journal of Heart Failure|August 30, 2021
Influence of endpoint definitions on the effect of empagliflozin on major renal outcomes in the EMPEROR-Preserved trialMilton Packer, Faiez Zannad, Javed Butler, et al.
Contemporary Clinical Trials|November 22, 2007
Quality management of a large randomized double-blind multi-centre trial: the ACTION experienceBridget-Anne Kirwan, Jacobus Lubsen, Sophie de Brouwer, et al.
The New England Journal of Medicine|November 16, 2010
Eplerenone in patients with systolic heart failure and mild symptomsFaiez Zannad, John J V McMurray, Henry Krum, et al.
Eurointervention : Journal of Europcr in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology|November 23, 2020
Prioritised endpoints for device-based hypertension trials: the win ratio methodologyDavid E Kandzari, Graeme L Hickey, Stuart J Pocock, et al.
European Journal of Heart Failure|December 27, 2021
Impact of anaemia and the effect of empagliflozin in heart failure with reduced ejection fraction: findings from EMPEROR-ReducedJoão Pedro Ferreira, Stefan D Anker, Javed Butler, et al.
European Heart Journal|December 8, 2021
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fractionJaved Butler, Milton Packer, Gerasimos Filippatos, et al.
Pageof 35